Rockwell Medical Reports $2.324 Million Third-Quarter Loss Despite 20% Sales Growth
Key Facts
Rockwell Medical reported on November 12 results for the three and nine months ended September 30, 2026, posting a third-quarter net loss of $2.324 million, compared with $1.753 million a year earlier. Basic and diluted loss per share was $0.59, compared with $0.49 in the year-earlier period. The wider loss coincided with a 20% increase in net sales to $19.1 million. Chief Executive Mark Strobek said sales growth reflected "customer adoption of the products and validation of their market fit." The company released the results on the same day it had scheduled its quarterly discussion webcast, putting operating performance and losses at the forefront of investor attention.
Gross profit rose 37% year over year in the third quarter, with the company attributing the increase mainly to higher volumes. The increase in gross profit points to improved value from sales during the period, alongside higher net sales than a year earlier. But this improvement did not prevent net loss from rising to $2.324 million from $1.753 million. Loss per share also increased to $0.59 from $0.49, showing that revenue and gross-profit growth did not translate into a lower net loss during the quarter. Strobek said customers had adopted the products, describing that as validation of their market fit.
For the first nine months of 2026, net sales were $54.238 million, compared with $50.912 million in the same period of 2025. Gross profit for the period rose to $9.251 million from $7.817 million. These figures place third-quarter growth within the year-to-date trend: nine-month sales exceeded the prior-year level, and gross profit also increased. In the second quarter, sales were $17.8 million, up 11% year over year, while the company posted a net loss of $1.2 million, compared with $1.5 million a year earlier. Sales growth reported in the third quarter therefore accelerated from the second-quarter rate, while net loss widened year over year in the third quarter.
In August, the company maintained its 2026 sales guidance of between $70.0 million and $75.0 million, gross margin of between 18% and 22%, and adjusted earnings before interest, taxes, depreciation and amortization of between $1.0 million and $2.0 million. It also forecast positive operating cash flow. The quarterly results put sales growth and improved gross profit in the context of these annual targets, while the third-quarter loss remains part of the operating picture. The company had reported second-quarter growth of 11% year over year before it rose to 20% in the third quarter. The results reported here did not include an update to the guidance the company announced in August.
The results follow Rockwell Medical's November 3 announcement of an agreement to acquire Vantive's global business in dialysis concentrates and equipment, water treatment systems, consumables and technical services. The company estimated that the combined businesses could generate annual revenue of between $400 million and $450 million after the deal closes, subject to assumptions including operating performance, exchange rates, market conditions and successful integration. The agreement set a total base purchase price of $125 million, funded by two term loans of $50 million each and a $25 million convertible note. It also includes contingent additional consideration of up to $45 million, tied to revenue and adjusted earnings before interest, taxes, depreciation and amortization targets. The deal remains part of the company's future plans, with closing expected in mid-2027.
According to EL7 data, RMTI shares closed at $7.08 on November 11, 2026, before the results were announced on November 12. The company scheduled a results discussion webcast, followed by discussion and a question-and-answer session, for November 12 at 8:00 a.m. Eastern time. This followed the company's announcement that it would release results on November 12, which it did on the scheduled date. The webcast gives the company an opportunity to discuss third-quarter results with investors on the day of the announcement. The Vantive deal is expected to close in mid-2027.